Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Cantor starts Ocugen at OW; PT $4.50

Cantor Fitzgerald launched coverage of Ocugen (NASDAQ:OCGN) with an “overweight” rating and price target of $4.50. The stock closed at $2.17 on June 1. Ocugen is a clinical-stage biotechnology company focused on...

June 2, 2022

Markets

Cantor starts Gracell Biotechnologies at OW; PT $20

Cantor Fitzgerald initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “overweight” rating and $20 price target. The stock closed at $3.29 on May 31. Gracell is a clinical-stage biopharmaceutical company...

June 1, 2022

Markets

BTIG starts NexImmune at buy; PT $5

BTIG initiated coverage of NexImmune (NASDAQ:NEXI) with a “buy” rating and price target of $5. The stock closed at $2.28 on May 31. NexImmune exploits signals naturally provided by dendritic cells (DCs) to activate...

May 31, 2022

Markets

SVB Securities starts PepGen at OP; PT $40

SVB Securities launched coverage of PepGen (NASDAQ:PEPG) with an “outperform” rating and $40 price target. The stock closed at $10.88 on May 27. PepGen is a clinical-stage biotech advancing its enhanced delivery...

May 31, 2022

Markets

BTIG starts Liquidia at buy; PT $14

BTIG initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $14 price target. The stock closed at $4.07 on May 27. Analyst Julian Harrison writes that Liquidia has brought its lead candidate, YUTREPIA, to...

May 31, 2022

Markets

SVB cuts Avadel Pharma PT to $6 from $18

SVB Securities slashed the price target of Avadel Pharmaceuticals (NASDAQ:AVDL) to $6 from $18, but maintained an “overweight” rating, after the FDA delayed full approval of FT-218 because of a patent issue. Shares of...

May 27, 2022

Markets

Maxim reduces PTs in challenging biotech market

Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...

May 26, 2022

Markets

Cantor starts Pliant Therapeutics at OW; PT $12

Cantor Fitzgerald launched coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.93 on May 24. Pliant is developing novel therapies for...

May 25, 2022

Markets

Cantor starts Lyra Therapeutics at OW; PT $15

Cantor Fitzgerald initiated coverage of Lyra Therapeutics (NASDAQ:LYRA) with an “overweight” rating and price target of $15. The stock closed at $6.07 on May 23. Lyra is a clinical-stage company developing medicines...

May 24, 2022

Markets

Analysts start HilleVax at buy, outperform

Analysts for Stifel and SVB Securities initiated coverage of HilleVax (NASDAQ:HLVX) with “buy” and “outperform” ratings, and price targets of $34 and $30, respectively. The stock closed at $9.50 on May 23. The company’s...

May 24, 2022

Markets

Piper cuts Humacyte to underweight; PT to $4 from $10

Piper Sandler downgraded Humacyte (NASDAQ:HUMA) to “underweight” from “overweight” and reduced its price target to $4 from $10, citing the sizable stock pullback in the sector. The stock closed at $5.37 on May 13. The...

May 16, 2022

Markets

BTIG slashes 89bio PT to $28 from $60

BTIG reduced its price target for 89bio (NASDAQ:ETNB) to $28 from $60 but maintained its “buy” rating after making model updates and increasing its modeled discount rate to 14% from 12%. The stock closed at $2.67 on May...

May 13, 2022

Markets

HCW cuts Pulse Biosciences to neutral; withdraws PT

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...

May 13, 2022

Markets

BTIG halves Poseida Therapeutics PT to $20 from $40

BTIG slashed its price target for Poseida Therapeutics (NASDAQ:PSTX) to $20 from $40 but maintained its “buy” rating after increasing its modeled discount rate to 14% from $12, given current market conditions. The stock...

May 13, 2022

Markets

Leede Jones Gable starts ProMIS at speculative buy; PT 50 cents (Canadian)

Leede Jones Gable initiated coverage of ProMIS Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents (Canadian). The stock closed at 11 cents on May 10. The firm’s lead preclinical...

May 11, 2022

Markets

BTIG starts Athira Pharma at buy; PT $33

BTIG launched coverage of Athira Pharma (NASDAQ:ATHA) with a “buy” rating and $33 price target. The stock closed at $8.84 on May 9. Athira is developing fosgonimeton for the treatment of Alzheimer’s disease, pervasive...

May 10, 2022

Markets

Maxim starts Oncternal at buy; PT $3.50

Maxim Group initiated coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 9. Oncternal is a clinical-stage company focused on novel targets...

May 10, 2022

Markets

Maxim cuts 180 Life Sciences to hold; withdraws PT

Maxim Group downgraded 180 Life Sciences (NASDAQ:ATNF) to “hold” from “buy” and withdrew its price target, citing a financing overhang. The stock closed at $1.31 on May 6. Several weeks ago, 180 announced the...

May 9, 2022

Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022

Markets

SVB cuts Aligos to market perform; PT to $3 from $7

SVB Securities downgraded Aligos Therapeutics (NASDAQ:ALGS) to “market perform” from “outperform” and slashed its price target to $3, which is close to cash, from $7, citing a slow catalyst path ahead with a legal...

May 5, 2022

Markets

HCW starts Shattuck Labs at buy; PT $28

H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...

May 2, 2022

Markets

HCW starts Vera Therapeutics at buy; PT $35

H.C. Wainwright launched coverage of Vera Therapeutics (NASDAQ:VERA) with a “buy” rating and $35 price target. The stock closed at $20 on April 29. Vera is a clinical-stage biotech company focused on developing disease...

May 2, 2022

Subscribe